Schedule of Indefinite Lived Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified |
Dec. 31, 2012
|
Dec. 31, 2011
|
---|---|---|
Indefinite-lived Intangible Assets [Line Items] | ||
Net carrying value | $ 63,689 | $ 70,396 |
In Process Research And Development | U.S. Marketing Rights For Firdapse
|
||
Indefinite-lived Intangible Assets [Line Items] | ||
Net carrying value | 0 | 6,707 |
In Process Research And Development | BMN-673 acquired through LEAD
|
||
Indefinite-lived Intangible Assets [Line Items] | ||
Net carrying value | 36,089 | 36,089 |
In Process Research And Development | BMN-701 Acquired Through Zystor
|
||
Indefinite-lived Intangible Assets [Line Items] | ||
Net carrying value | 25,010 | 25,010 |
In Process Research And Development | Other Acquired Pre-Clinical Compounds
|
||
Indefinite-lived Intangible Assets [Line Items] | ||
Net carrying value | $ 2,590 | $ 2,590 |